Aggressive B-Cell Lymphomas: Clinical Application of New Advances in Community Practice

Learn current and novel best-practice strategies for the treatment of patients with mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL) in these interactive, expert-led 1-hour workshops.

Agenda

  • Program Overview
  • New Advances in Aggressive B-Cell Lymphomas
    • Mantle cell lymphoma (MCL)
    • Diffuse large B-cell lymphoma (DLBCL)
  • Selecting Treatments for MCL and DLBCL
  • Managing Treatment-Related Adverse Events
  • Addressing Key Challenges and Future Directions in MCL and DLBCL
  • Closing Remarks and Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Program Director
Ian W. Flinn, MD, PhD

Director, Lymphoma Research Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with aggressive B-cell lymphomas.

Target Audience
This program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with B-cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order and interpret molecular profiling for appropriate patients with aggressive B-cell lymphoma to guide therapy selection
  • Select treatment regimens for patients with MCL and DLBCL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with aggressive B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of aggressive B-cell lymphomas

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN Live Meetings: JA4008176-0000-21-240-L01-P

UAN Virtual: JA4008176-0000-21-241-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.